Crizotinib is a type of targeted cancer drug. It is a treatment for advanced non small cell lung cancer (NSCLC). It is for NSCLC that has changes in either a gene called anaplastic lymphoma kinase (ALK) or ROS1. Your doctor checks your cancer for these gene changes.
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of Crizotinib Capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Crizotinib Capsules medicine cost price in India.
The order for Crizotinib Capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
XALKORI® (crizotinib) Capsules, oral Initial U.S. Approval: August 2011
Generic Name: crizotinib
XALKORI Capsules: 250 mg and 200 mg.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Crizotinib Capsules on prescription and Import License in Patient's Name only.
For overseas patients, Crizotinib Capsules can be made available in Send your enquiry to find Crizotinib Capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For XALKORI (crizotinib) Capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Dr. Saxena on Treatment Options in ALK+ NSCLC For More Details
Xalkori-Alecensa sequential therapy advantageous in duration of treatment
Dated: Sunday, Mar 11, 2018